



MAVDA Newsletter

11 November 2024 | Issue 6



As we enter the third quarter of the third year of the MAVDA initiative, we are pleased to report significant progress across our consortium projects. Notable publications are forthcoming, highlighting the discovery of novel antiviral targets and the development of innovative technology platforms aimed at accelerating antiviral drug discovery. Moving forward, it is crucial that we maintain momentum and continue advancing our programs toward the IND-enabling stage. We anticipate entering a no-cost extension phase, which will be initiated in April 2025.



Important Dates and Recent Updates



NIH NIAID Quarterly Meeting

The next quarterly update with NIH is on the 12th of December. Please send the updates of your projects/cores in a PPT format (2-3 slides).

More details to follow by email.

Annual MAVDA Retreat



MAVDA Retreat Dinner*

23rd January, Thursday | 6-9 PM

*Only for Core/Project directors, DRP/MRP investigators and SAB members

MAVDA Annual Scientific Meeting

24th January, Friday | 10 AM - 4 PM

CDI, 111 Ideation Way, Nutley, NJ

[Register now!](#)



Virology Core Resources

Our virology core has continuously enhanced its capabilities to stay prepared for emerging viral pandemic threats.

For more details on available assays and viral strains, please refer to our [brochure](#).